Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiten D Patel

Showing results (221-230 of 243) with videos related to

Pageof 25
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 10, 2025
Utility of <sup>18</sup>F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomyEric V Li, Edward M Schaeffer, Sai Kaushik Shankar Ramesh Kumar, et al.
European Urology|May 24, 2020
Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical TrialHiten D Patel, Farzana A Faisal, Bruce J Trock, et al.
NPJ Precision Oncology|March 20, 2026
Prediction of molecular subtypes from histology: AI-driven analysis of prostate cancer morphological patterns and therapeutic implicationsRamin Nateghi, Aoran Sun, Hao Dang, et al.
The Journal of Urology|September 28, 2017
Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM RegistryAkachimere C Uzosike, Hiten D Patel, Ridwan Alam, et al.
Molecular Oncology|September 27, 2023
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapyGoran Rac, Hiten D Patel, Christopher James, et al.
Cancer|July 12, 2022
Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesionsAndrew M Fang, Luke A Shumaker, Kimberly D Martin, et al.
European Urology Oncology|May 11, 2025
Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate CancerNicole Handa, Eric V Li, Jamie Michael, et al.
The Journal of Urology|August 27, 2021
Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and SurvivalHiten D Patel, Sunil H Patel, Enrique Blanco-Martinez, et al.
European Urology Oncology|May 29, 2021
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell CarcinomaMichael A Gorin, Hiten D Patel, Steven P Rowe, et al.
Urology|October 17, 2017
Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery EraAlice Semerjian, Niv Milbar, Max Kates, et al.
Pageof 25

Showing results (221-230 of 243) with videos related to

Sort By:
Pageof 25
European Journal of Nuclear Medicine and Molecular Imaging|February 10, 2025
Utility of <sup>18</sup>F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomyEric V Li, Edward M Schaeffer, Sai Kaushik Shankar Ramesh Kumar, et al.
European Urology|May 24, 2020
Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical TrialHiten D Patel, Farzana A Faisal, Bruce J Trock, et al.
NPJ Precision Oncology|March 20, 2026
Prediction of molecular subtypes from histology: AI-driven analysis of prostate cancer morphological patterns and therapeutic implicationsRamin Nateghi, Aoran Sun, Hao Dang, et al.
The Journal of Urology|September 28, 2017
Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM RegistryAkachimere C Uzosike, Hiten D Patel, Ridwan Alam, et al.
Molecular Oncology|September 27, 2023
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapyGoran Rac, Hiten D Patel, Christopher James, et al.
Cancer|July 12, 2022
Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesionsAndrew M Fang, Luke A Shumaker, Kimberly D Martin, et al.
European Urology Oncology|May 11, 2025
Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate CancerNicole Handa, Eric V Li, Jamie Michael, et al.
The Journal of Urology|August 27, 2021
Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and SurvivalHiten D Patel, Sunil H Patel, Enrique Blanco-Martinez, et al.
European Urology Oncology|May 29, 2021
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell CarcinomaMichael A Gorin, Hiten D Patel, Steven P Rowe, et al.
Urology|October 17, 2017
Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery EraAlice Semerjian, Niv Milbar, Max Kates, et al.
Pageof 25